AIT Therapeutics, Inc. (OTCMKTS:KKICD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
AIT Therapeutics, Inc., a Delaware corporation (the
Company), appointed Mr. Hai Aviv to serve as the Companys
Chief Financial Officer, effective as of February 28, 2017.
Ltd., a publicly-traded Israeli company listed on the Tel Aviv
Stock Exchange, operating in the fields of Internet, risk capital
investments and software, where he has served as Chief Financial
Officer from 2013 to the present. From 2010 to 2013, Mr. Aviv
served as Babylons corporate controller. Mr. Aviv is a certified
public accountant and, from 2005 to 2010, served as manager at
the Ernst Young Accounting Firm, Kost Forer, Gabbay Kasierer,
working predominantly with the high-tech team.
into an employment agreement (the Employment Agreement)
with the Companys wholly owned subsidiary, Advanced Inhalation
Therapies, Ltd., providing for annual compensation in an amount
equal to 420,000 New Israeli Shekels (NIS), or approximately
$113,400, based on an exchange rate of $0.27 per NIS. Severance
and disability benefits are generally provided as required under
Israeli law. Additionally, Mr. Aviv is entitled to a grant of
options to purchase 50,000 shares of the Companys common stock,
par value $0.0001, per share, subject to the Boards adoption of
an equity compensation plan and due authorization of such grant.
Under the Employment Agreement, Mr. Aviv has also agreed to
customary non-disclosure and non-competition covenants, and
either party may terminate the Employment agreement upon 90-days
prior written notice to the non-terminating party. The foregoing
description of the Employment Agreement is only a summary and is
qualified in its entirety by reference to the complete text of
the Employment Agreement, a copy of which is filed as Exhibit
10.1 to this Current Report on form 8-K and incorporated by
reference in this Item 5.02.
are no arrangements or understandings between Mr. Aviv and any
other person to which Mr. Aviv was selected as an officer of the
Company. Since the beginning of the Companys last fiscal year,
the Company has not engaged in any transaction, or any currently
proposed transaction, in which Mr. Aviv had or will have a direct
or indirect material interest in which the amount involved
exceeded or would exceed $120,000.
Employment Agreement, effective as of February 28, 2017 by
and between Advanced Inhalation Therapies, Ltd. and Hai
About AIT Therapeutics, Inc. (OTCMKTS:KKICD)
AIT Therapeutics, Inc., formerly KokiCare, Inc., is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations. The Company seeks to develop health care enterprise software to be sold to hospitals, medical centers and health care facilities in the United States and internationally. As of September 30, 2016, the Company had not generated any revenues. AIT Therapeutics, Inc. (OTCMKTS:KKICD) Recent Trading Information
AIT Therapeutics, Inc. (OTCMKTS:KKICD) closed its last trading session 00.00 at 30.00 with shares trading hands.